Zobrazeno 1 - 10
of 58
pro vyhledávání: '"Xiaopei Cui"'
Publikováno v:
ESC Heart Failure, Vol 11, Iss 5, Pp 2694-2706 (2024)
Abstract Aims Novel echocardiographic parameters of right ventricular (RV) function, including speckle‐tracking‐derived, three‐dimensional, and RV–pulmonary artery coupling parameters, have emerged for the evaluation of pulmonary arterial hyp
Externí odkaz:
https://doaj.org/article/fb96b9b819b7476a895045e2147374a5
Autor:
Shuai Zhang, Yishan Li, Yuanhua Yang, Sugang Gong, Zhenwen Yang, Cheng Hong, Xiaopei Cui, Jun Wan, Yingqun Ji, Hong Chen, Ling Zhu, Chenghong Li, Zhaozhong Cheng, Yunhui Zhang, Qiguang Wang, Qin Luo, Lu Guo, Guofeng Ma, Baoshi Han, Zhihong Liu, Changming Xiong, Lan Wang, Qiushang Ji, Fajiu Li, Shengfeng Wang, Zhu Zhang, Yunxia Zhang, Dingyi Wang, Qian Gao, Qiang Huang, Wanmu Xie, Zhenguo Zhai, Chen Wang
Publikováno v:
BMC Pulmonary Medicine, Vol 24, Iss 1, Pp 1-9 (2024)
Abstract Background Chronic thromboembolic pulmonary hypertension (CTEPH) is a progressive pulmonary vascular disorder with substantial morbidity and mortality, also a disease underdiagnosed and undertreated. It is potentially curable by pulmonary en
Externí odkaz:
https://doaj.org/article/026d62af1d194d9d84b39e756824c3a5
Autor:
Xiaojuan Ma, Shuang Zhang, Xiaochen Ren, Yujie Feng, Hui Li, Shi Chen, Jingen Xu, Yanting Wang, Guo-yuan Peng, Qingran Yan, Huifeng Jia, Simin Xia, Xiaopei Cui, Xiaofang Chen, Xianfei Pan, Shaojie Wang, Haijia Yu, Xiaoyue Wei, Mingwei Li, Bei Liu, Jingyue Xu, Qiaoxia Qian, Xiangyang Zhu, Yifan Zhan, Liangjing Lu
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Antibody drugs targeting single inflammatory cytokines have revolutionized the treatment of immune-mediated inflammatory diseases. To investigate whether dual targeting interleukin-17 (IL-17) and IL-36 enhances anti-inflammatory activity, bispecific
Externí odkaz:
https://doaj.org/article/e25db7dcba894a3da6c08a51ec9bda6c
Autor:
Tengfei Liu, Guopin Pan, Jing Zhang, Jianli Wang, Xiaosun Guo, Ye Chen, Xiaoyun Wang, Xiaopei Cui, Huiqing Liu, Fan Jiang
Publikováno v:
Heliyon, Vol 10, Iss 17, Pp e37227- (2024)
Our previous studies have shown that the novel selective RNA polymerase I inhibitor CX-5461 suppresses proliferation of vascular smooth muscle cells, mainly by inducing DNA damage response (DDR), including activations of ataxia telangiectasia mutated
Externí odkaz:
https://doaj.org/article/47f5538796374accb3417bae12bd29b2
Autor:
Chaochao Dai, Hongyu Zhang, Zhijian Zheng, Chun Guang Li, Mingyuan Ma, Haiqing Gao, Qunye Zhang, Fan Jiang, Xiaopei Cui
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
IntroductionMacrophage-mediated inflammatory response may have crucial roles in the pathogenesis of a variety of human diseases. Growth differentiation factor 15 (GDF15) is a cytokine of the transforming growth factor-β superfamily, with potential a
Externí odkaz:
https://doaj.org/article/293413a69da547e4952f928df7785a7c
Autor:
Jie Wang, Zhijian Zheng, Xiaopei Cui, Chaochao Dai, Jiaxin Li, Qunye Zhang, Mei Cheng, Fan Jiang
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
CX-5461, a novel selective RNA polymerase I inhibitor, shows potential anti-inflammatory and immunosuppressive activities. However, the molecular mechanisms underlying the inhibitory effects of CX-5461 on macrophage-mediated inflammation remain to be
Externí odkaz:
https://doaj.org/article/62fbbd220a474034bb5e75d7c1bcf0aa
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 9 (2022)
AimSelexipag is an oral selective prostacyclin receptor agonist approved for treatment of patients with pulmonary arterial hypertension (PAH). In the present study, we aim to assess the safety and efficacy of selexipag in triple combination therapy w
Externí odkaz:
https://doaj.org/article/a0343f8bad094ff6b3f3aa16478069d0
Autor:
Guopin Pan, Jing Zhang, Yu Han, Ye Chen, Xiaosun Guo, Xiaopei Cui, Mei Cheng, Haiqing Gao, Jianli Wang, Fan Jiang
Publikováno v:
Pharmacological Research, Vol 177, Iss , Pp 106120- (2022)
CX-5461 is a first-in-class selective RNA polymerase I inhibitor. Previously we found that CX-5461 had anti-inflammatory activities. In this study we characterized potential immunosuppressive effects of CX-5461 and explored the underlying mechanisms.
Externí odkaz:
https://doaj.org/article/2e4eb5730e554b4688de821dd961c102
Autor:
Jin Zhang, Yangyang He, Xiaosong Yan, Shanshan Chen, Ming He, Yuyang Lei, Jiao Zhang, Brendan Gongol, Mingxia Gu, Yifei Miao, Liang Bai, Xiaopei Cui, Xiaojian Wang, Yixin Zhang, Fenling Fan, Zhao Li, Yuan Shen, Chih‐Hung Chou, Hsien‐Da Huang, Atul Malhotra, Marlene Rabinovitch, Zhi‐Cheng Jing, John Y‐J Shyy
Publikováno v:
EMBO Molecular Medicine, Vol 12, Iss 5, Pp 1-13 (2020)
Abstract Endothelial dysfunction is critically involved in the pathogenesis of pulmonary arterial hypertension (PAH) and that exogenously administered microRNA may be of therapeutic benefit. Lower levels of miR‐483 were found in serum from patients
Externí odkaz:
https://doaj.org/article/9fca316f951a47569ae67456c7e5de14
Autor:
Xiaopei Cui, Huifeng Jia, Hong Xin, Lei Zhang, Shi Chen, Simin Xia, Xue Li, Wei Xu, Xiaofang Chen, Yujie Feng, Xiaoyue Wei, Haijia Yu, Yanting Wang, Yifan Zhan, Xiangyang Zhu, Xuemei Zhang
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Therapeutic monoclonal antibodies (mAbs) blocking immune checkpoints have been mainly used as monotherapy. Recently, combination therapy targeting multiple immune checkpoints has recently been explored to increase anti-cancer efficacy. Particularly,
Externí odkaz:
https://doaj.org/article/a3b267fa67544fc5a32b0e5de324c6a1